Neoadjuvant immunotherapy (talimogene laherparepvec) vs no neoadjuvant treatment
Quality of life ‐ not measured · stage III and IV cutaneous melanoma
The review found no eligible studies for this question.
1 finding from 1 review
- Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found